Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

Liposome encapsulation of anticancer agents results in reduced side effects of the entrapped drug and improved therapeutic efficacy. The external surface of the lipidic envelope can be coupled with antibodies directed against tumor-associated antigens. The resulting immunoliposomes allow to increase the therapeutic index of cytotoxic drugs while minimizing their systemic toxicity. In this regard, the disialoganglioside GD2 is a very promising tumor-associated antigen since it is expressed at high intensity on human neuroblastoma cells, but is detected only in normal cerebellum and peripheral nerves. Immunoliposomes can be used as vectors to deliver antisense oligonucleotides to cancer cells with the aim to modulate oncogene expression. Furthermore, antisense oligonucleotides have attracted much interest because of their ability to stimulate immune responses. Here, we will describe a novel experimental therapeutic approach for neuroblastoma based on anti-GD2 liposomal c-myb-selective antisense oligonucleotides.

[1]  S. Crooke.  Progress toward oligonucleotide therapeutics: pharmacodynamic properties , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  K. Mujoo,et al.  Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. , 1987, Cancer research.

[3]  A. Donfrancesco,et al.  Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T Ochi,et al.  A comparison of in vivo gene delivery methods for antisense therapy in ligament healing , 1998, Gene Therapy.

[5]  Gunther Hartmann,et al.  Antisense therapy in oncology: new hope for an old idea? , 2001, The Lancet.

[6]  D. Stuart,et al.  A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. , 2000, Biochimica et biophysica acta.

[7]  B. Calabretta,et al.  Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. , 2000, Journal of the National Cancer Institute.

[8]  A. Dritschilo,et al.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. , 1992, Nucleic acids research.

[9]  Gunther Hartmann,et al.  Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 , 2000, The Journal of Immunology.

[10]  D. Ribatti,et al.  Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[12]  T. Allen,et al.  Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. , 2004, Journal of the National Cancer Institute.

[13]  M. Hope,et al.  Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[15]  T. Allen,et al.  Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. , 2003, Cancer letters.

[16]  E. Moase,et al.  Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. , 2003, Cancer research.

[17]  P. Cornaglia-Ferraris,et al.  Uncoordinate induction and differential regulation of hla class‐I and class‐II expression by γ‐interferon in differentiating human neuroblastoma cells , 1993, International journal of cancer.

[18]  G. Zon,et al.  Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. , 1993, Antisense research and development.

[19]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[20]  R. Purcell,et al.  Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[21]  R. Wagner.  The state of the art in antisense research , 1995, Nature Genetics.

[22]  D. Stuart,et al.  A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1 , 2000, Cancer Gene Therapy.

[23]  V. Soldatenkov,et al.  Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer , 1997, Gene Therapy.

[24]  K K Matthay,et al.  Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Ferraris,et al.  Synergistic Differentiation-Promoting Activity of Interferon γ and Tumor Necrosis Factor-α: Role of Receptor Regulation on Human Neuroblasts , 1994 .

[26]  B. Calabretta,et al.  Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines. , 1992, Cancer research.

[27]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[28]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.